Lymphoma oncologist at Brown University / Rhode Island Hospital
Brown University
Joined November 2014
- Tweets120
- Following130
- Followers719
- Likes150
Adam Olszewski MD retweeted
New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
thelancet.com/journals/lanha…
Adam Olszewski MD retweeted
Delighted to share our work now published on behalf of all co-authors.
Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL.
Thank you so much to all international collaborators!
ascopubs.org/doi/10.1200/JCO…
For systemic #CTCL /MF/SS, @BrownHeme we choose #immunotherapy a lot. Reviewing T-cell containment options: kill'em, poison'em, PD1-knock'em. But really we should be turning them against each other... ncbi.nlm.nih.gov/pmc/article… @OllilaTom #lymsm
Adam Olszewski MD retweeted
🙌TY to all collaborators (@sairah__ahmed, @LNastoupilMD, @uroosaibrahim, @NEpperla, @tvoorheesmd, @lymphomatic etc) & @RutgersCancer fellow Dr McKenna on this #RWE of #CART for rel/ref SOT-PTLD. We describe immunosupression, toxicity & outcomes. @BrJHaem
onlinelibrary.wiley.com/doi/…
Adam Olszewski MD retweeted
East coast friends! @JohnPLeonardMD gave @lymphomatic and I the challenge of debating the utility of CNS prophylaxis in DLBCL. Come learn and watch us duke it out on 04/13 in NYC! Register now: okt.to/7oIirY @GreatDebatesCME #bloodcancer #HematologicMalignancies
Adam Olszewski MD retweeted
Check out our study on function, treatment, and outcomes in nursing home patients w/ DLBCL- a population very challenging to manage!
Glad to see this published. This concludes a series of projects on older pts w/ aggressive lymphoma that are very close to my heart! @lymphomatic
Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study. agsjournals.onlinelibrary.wi… #geriatrics
Adam Olszewski MD retweeted
Editorial: The demise of Roe v Wade: a hematologist’s perspective loom.ly/MkH8V3g
Adam Olszewski MD retweeted
Defining and treating high-grade B-cell #lymphoma, NOS ashpublications.org/blood/ar…
TY to @BrownMedicine @lymphomatic & @BrownUniversity Dr Kurt collab on this review.
2 new classifications out since this was pre-published ~1 year ago but most content still valid/relevant!
#lymsm
Adam Olszewski MD retweeted
#COVID19 booster vaccination leads to seroconversion in over 1/2 of patients w/ hematologic malignancies who had undetectable antibodies to the initial vaccine series. The risk of death appears highest in those with undetectable antibodies. acsjournals.onlinelibrary.wi… @OncoAlert
#boosters work for >50% of pts with #lymphoma who did not respond to initial vaccine. On or off treatment. Boosters + #Evusheld have largely eliminated #COVID deaths (in our center) #lymsm @JournalCancer @ASH_hematology doi.org/10.1002/cncr.34354
Adam Olszewski MD retweeted
Register at bit.ly/3GWO3nN to hear the latest research & info on aggressive #lymphoma from Dr. David Scott, @lymphomatic, Dr. Neha Mehta-Shah & Dr. Dan Landsburg at #IUCLS2022! Join us live in Chicago April 29-30! @UChicagoCME
We detected clonotypic DNA in the CSF of 36% #DLBCL pts @ high CNS relapse risk. (+)CSF = 29% risk of CNS relapse, (-)CSF assay = 0% risk. If validated - maybe a new way to help personalize CNS prophylaxis? doi.org/10.1182/bloodadvance… #lymsm @BloodAdvances @AdaptiveBiotech @BrownHeme
Adam Olszewski MD retweeted
Defining and Treating High-grade B-cell #lymphoma, NOS | @BloodJournal @ASH_hematology ashpublications.org/blood/ar…
Happy to publish this review w/ @RIHospital @BrownUCancer @lymphomatic & Dr Kurt on the challenging topic/entity of HGBL-NOS (1st pic below is correct Fig 1). #lymsm
Adam Olszewski MD retweeted
The future of CLL therapy has arrived: our ph2 AVO trial in 1L CLL from @DanaFarber and @BIDMChealth with support from @AstraZeneca and @genentech is now online @TheLancetOncol authors.elsevier.com/a/1dlF4…
(2) Pts with #lymphoma have low responses to standard #CovidVaccine. + (2) CDC recommends #boosterdose for immunosuppressed = (4) If you had a CD20 antibody or are on active therapy for lymphoma, you're included. #lymsm @ASH_hematology @lymphoma jamanetwork.com/journals/jam…
Adam Olszewski MD retweeted
Honored Jama Onc has published our work. Please get yourself vaccinated for those in whom it does not work. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease ja.ma/3iCBPXS via @JAMAOnc part of @JAMANetwork
Adam Olszewski MD retweeted
Kudos to @BrownUniversity @RIHospital Adam & Adam (@lymphomatic) on detailed #RWE analysis of CNS involvement in Burkitt #lymphoma.
Several interesting nuggets of info gleaned (incidence, characteristics, outcomes, etc).
Early View | Haematologica haematologica.org/article/vi… #lymsm
Adam Olszewski MD retweeted
Thanks much 👏 @chanyooncheah (and @CwynKate, @graham74GC, Dr El-Galaly & many others) for collaborating on this work!
It was great to combine International forces to analyze 1,000+ Burkitt #lymphoma patients and generate/validate this prognostication index (aka #BLIPI). #lymsm
Congrats @lymphomatic @DrAEvens et al on leading this collaboration @JCO_ASCO Burkitt Lymphoma International Prognostic Index (aka BLIPI)
#lymSM
- age≥40, ECOG≥2, LDH≥3xULN = 1 point
- 0, 1, 2+ factors = 3-year PFS 92, 72 ,53%
ascopubs.org/doi/abs/10.1200…
Adam Olszewski MD retweeted
Our study evaluating prognostic factors driving Burkitt lymphoma outcome is out in this issue of @BloodJournal Thank you to all investigators for their contribution. @DrAEvens @lymphomatic
ashpublications.org/blood/ar…
Adam Olszewski MD retweeted
The Burkitt Lymphoma International Prognostic Index Andrew M. Evens, DO, MSc @DrAEvens @RutgersCancer #ASH20 #Lymphoma #Cancer #Research
Link To Full Video:
oncologytube.com/video/39713…